Previous close | 180.47 |
Open | 180.48 |
Bid | 186.00 |
Ask | 193.00 |
Strike | 850.00 |
Expiry date | 2025-01-17 |
Day's range | 180.47 - 180.48 |
Contract range | N/A |
Volume | |
Open interest | 202 |
First Quarter Results Show Revenue Decline but Strong Dupixent and Libtayo Sales Growth
It is hard to get excited after looking at Regeneron Pharmaceuticals' (NASDAQ:REGN) recent performance, when its stock...
First quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023; excluding RonapreveTM(a)(b), revenues increased 7%First quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 24% to $3.08 billion versus first quarter 2023First quarter 2024 U.S. net sales for EYLEA® HD and EYLEA® were $1.40 billion, including $200 million from EYLEA HDFirst quarter 2024 Libtayo® global net sales increased 45% to $264 million versus first quarter 2023First quarter 2024 GAAP dil